Almirall Second Quarter 2025 Earnings: EPS: €0.023 (vs €0.037 in 2Q 2024)
Almirall (BME:ALM) Second Quarter 2025 Results
Key Financial Results
- Revenue: €277.3m (up 10% from 2Q 2024).
- Net income: €4.98m (down 38% from 2Q 2024).
- Profit margin: 1.8% (down from 3.2% in 2Q 2024). The decrease in margin was driven by higher expenses.
- EPS: €0.023 (down from €0.037 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Almirall Earnings Insights
Looking ahead, revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe.
Performance of the market in Spain.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Almirall that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BME:ALM
Almirall
Operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.
Flawless balance sheet with reasonable growth potential.
Similar Companies
Market Insights
Community Narratives


